Supernus Announces New Qelbree® Data Showing Improvemen

Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant...

Related Keywords

United States , Alice Sofield , Peter Vozzo , Jacka Khattar , Las Vegas , Ann Childress , Andrewj Cutler , Timothyc Dec , Jonathan Rubin , Psych Congress , Nasdaq , Neuroscience Education Institute , Securities Exchange , Supernus Pharmaceuticals , Research Development , Supernus Pharmaceuticals Inc , Exchange Commission , Chief Medical Officer , Senior Vice President , Concomitant Use , Behavioral Medicine , Open Label Extension Trial , Symptom Rating Scale , Global Executive Composite , Clinical Associate Professor , Medical University , Neuroscience Education , Prescribing Information , Boxed Warning , Private Securities Litigation Reform Act , Securities Exchange Act , Nasdaq Supn , Nc ,